Axl-targeting drugs in tumor therapy: Research advances / 国际药学研究杂志

ABSTRACT

Axl belongs to the family of receptor tyrosine kinase. Axl and its ligand Gas6 are aberrantly over-expressed in numerous human cancers. The binding of Gas6 and Axl could activate multiple signaling pathways, which take part in the development and progression of cancer, including cell survival, migration, invasion, and angiogenesis. In recent years, Axl and Gas6 have been considered as a promising novel target for cancer therapeutics. Several Axl inhibitors, including small-molecule tyrosine kinase inhibitors and anti-Axl monoclonal antibodies are currently under research. In this paper, we review the development of Axl-targeting drugs in tumor therapy.